Form 4: Precision BioSciences CFO Acquires Shares in Open Market Transaction

Precision BioSciences' Chief Financial Officer, John Alexander Kelly, purchased 2,113 shares of common stock at $4.75 per share on December 27, 2024.

Summary

• John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, Inc., acquired 2,113 shares of the company's common stock on December 27, 2024.
• The shares were purchased at a price of $4.75 each.
• Following this transaction, Mr. Kelly directly owns 40,186 shares of Precision BioSciences common stock.

Sentiment

Score: 6

Explanation: The document is a neutral report of a stock purchase by an insider. It is neither particularly positive nor negative, but the purchase could be interpreted as a sign of confidence.

Positives

• The CFO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a routine Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of key personnel.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transaction is relatively small in terms of volume and value, and is not unusual for a CFO of a company of this size.

Stakeholder Impact

• The stock purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Precision BioSciences, John Alexander Kelly, CFO, stock purchase, insider trading, DTIL, common stock